Identification | Back Directory | [Name]
5-amino-2-(((6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)-4-(3-(2-aminoethyl)ureido)-1-methyl-1H-pyrazol-2-iumhydrogensulfate | [CAS]
936111-69-2 | [Synonyms]
FR264205 FR-264205 FR 264205 5-amino-2-(((6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)-4-(3-(2-aminoethyl)ureido)-1-methyl-1H-pyrazol-2-iumhydrogensulfate | [Molecular Formula]
C23H32N12O12S3 | [MOL File]
936111-69-2.mol | [Molecular Weight]
764.768 |
Hazard Information | Back Directory | [Uses]
Ceftolozane Sulfate is an antibiotic belonging to the class of Cephalosporin (Cephalosporin C Zinc Salt, C258750). | [in vivo]
Ceftolozane (400-800 mg/kg, s.c., every 6 h) sulfate reduces ESBL-producing Enterobacteriaceae in neutropenic mice[6].
Ceftolozane (180 mg/kg, s.c., every 8 h, 48 h) sulfate reduces bacterial load and improves early pulmonary inflammatory response without impairing 48 h post-infection homeostasis in a mice model of Pseudomonas aeruginosa acute pneumonia[7].
Animal Model: | Neutropenic murine thigh infection model[6] | Dosage: | 400, 800 mg/kg | Administration: | Subcutaneous injection (s.c.), every 6 h | Result: | Reduced ESBL-producing Enterobacteriaceae.
Showed that ceftolozane with tazobactam at a 2:1 ratio were significantly different than animals treated with ceftolozane alone.
|
|
|
|